---
title: "Trulicity (dulaglutide) in type 2 diabetes: Dosing and administration questions"
description: "Dosing and administration questions on Trulicity (dulaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Treatment combinations, Dosing, and Administration. Questions: Can Trulicity be used with an SGLT2 inhibitor? Can Trulicity be used with basal insulin? What is the Trulicity dosing schedule for adults? What is the maximum dose of Trulicity? 2 further questions follow. 6 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/dosing-and-administration"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide) in type 2 diabetes: Dosing and administration questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)

Dosing and administration questions that apply to every indication of Trulicity are on [Trulicity (dulaglutide), all indications: Dosing and administration](https://www.evicenter.com/medical-information/trulicity/dosing-and-administration).

## Treatment combinations

<a id="trulicity-with-sglt2-inhibitor"></a>

### Can Trulicity be used with an SGLT2 inhibitor?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In this 24-week placebo-controlled, double-blind trial, 423 adult patients were randomized to and received TRULICITY 0.75 mg, TRULICITY 1.5 mg, or placebo, as add-on to sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy (96% with and 4% without metformin).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%2024%2Dweek%20placebo%2Dcontrolled%2C%20double%2Dblind%20trial%2C%20423,with%20and%204%25%20without%20metformin%29.)

> “At 24 weeks, treatment with once weekly TRULICITY 0.75 mg and 1.5 mg resulted in a statistically significant reduction from baseline in HbA1c compared to placebo (Table 9).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=At%2024%20weeks%2C%20treatment%20with%20once%20weekly%20TRULICITY%200.75,compared%20to%20placebo%20%28Table%209%29.)

> “Table 9: Results at Week 24 of TRULICITY as Add-on to SGLT2i in Adult Patients with Type 2 Diabetes Mellitusa
>
> Abbreviations: HbA1c = hemoglobin A1c; SGLT2i = sodium-glucose co-transporter-2 inhibitors.
>
>
>
>
> a Intent-to-treat population. At Week 24, primary efficacy was missing for 3%, 4%, and 6% of individuals treated with placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, respectively.
>
>
>
>
> b Least-squares mean adjusted for baseline value and other stratification factors. Placebo multiple imputation, using baseline and 24-week values from the placebo arm, was applied to model a washout of the treatment effect for patients missing 24-week values (HbA1c, fasting serum glucose, and body weight).
>
>
>
>
> c Patients with missing HbA1c data at Week 24 were considered as non-responders.
>
>
>
>
> †† p<0.001 for superiority of TRULICITY compared to placebo, overall type I error controlled.
>
>
> 	24-Week Primary Time Point
> Placebo	TRULICITY
> 0.75 mg	TRULICITY
> 1.5 mg
> Intent-to-Treat (ITT) Population (N)	140	141	142
> HbA1c (%) (Mean)
> Baseline	8.1	8.1	8.0
> Change from baselineb	-0.6	-1.2	-1.3
> Difference from placebob (95% CI)	-	-0.7 (-0.8, -0.5)††	-0.8 (-0.9, -0.6)††
> Percentage of patients HbA1c <7.0%c	31	59††	67††
> Fasting Serum Glucose (mg/dL) (Mean)
> Baseline	153	162	161
> Change from baselineb	-6	-25	-30
> Difference from placebob (95% CI)	-	-19 (-25, -13)	-24 (-30, -18)††”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Table%209%3A%20Results%20at%20Week,%2D24%20%28%2D30%2C%20%2D18%29%E2%80%A0%E2%80%A0)

Note: Table 9 columns are placebo, TRULICITY 0.75 mg, and TRULICITY 1.5 mg, in that order.

<a id="trulicity-with-insulin"></a>

### Can Trulicity be used with basal insulin?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Basal insulin can be titrated as needed and combined with any dose of once-weekly Trulicity.<sup>1</sup>”

Source: [TRULICITY: Resources for HCPs – Videos & FAQs, captured 2026-11-13](https://trulicity.lilly.com/hcp/resources#faq:~:text=Basal%20insulin%20can%20be%20titrated,with%20any%20dose%20of%20once%2Dweekly)

> “When using TRULICITY with insulin, administer as separate injections and never mix. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=When%20using%20TRULICITY%20with%20insulin%2C,be%20adjacent%20to%20each%20other.)

> “In this 28-week placebo-controlled, double-blind trial, 300 adult patients were randomized to placebo or once weekly TRULICITY 1.5 mg, as add-on to titrated basal insulin glargine (with or without metformin). Patients had a mean age of 60 years; mean duration of type 2 diabetes of 13 years; 58% were male; race: White, Black, and Asian were 94%, 4%, and 0.3%, respectively; and 20% of the trial population was in the US.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20this%2028%2Dweek%20placebo%2Dcontrolled%2C%20double%2Dblind,population%20was%20in%20the%20US.)

> “At 28 weeks, treatment with once weekly TRULICITY 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo (Table 11).”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=At%2028%20weeks%2C%20treatment%20with,compared%20to%20placebo%20%28Table%2011%29.)

> “When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=When%20initiating%20TRULICITY%2C%20consider%20reducing,%285.3%29%20and%20Adverse%20Reactions%20%286.1%29%5D.)

Note: The placebo-controlled basal insulin trial in the Prescribing Information studied TRULICITY 1.5 mg.

## Dosing

<a id="trulicity-dosing-adults"></a>

### What is the Trulicity dosing schedule for adults?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].
> After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control.
> If additional glycemic control is needed, increase the dosage in 1.5 mg increments after at least 4 weeks on the current dosage.
> The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20recommended%20starting%20dosage%20of,4.5%20mg%20injected%20subcutaneously%20once%20weekly.)

<a id="trulicity-max-dose"></a>

### What is the maximum dose of Trulicity?

Applies to: Glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=The%20maximum%20recommended%20dosage%20is%204.5%20mg%20injected%20subcutaneously%20once%20weekly.)

> “If additional glycemic control is needed, increase dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=If%20additional%20glycemic%20control%20is%20needed%2C%20increase%20dosage%20to,on%20the%200.75%20mg%20dosage.)

Note: The 4.5 mg maximum applies to adults; the 1.5 mg maximum applies to pediatric patients 10 years of age and older.

<a id="trulicity-dosing-children"></a>

### What is the Trulicity dose for children 10 years and older?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly.
> If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=2.2%20Pediatric%20Dosage-,The%20recommended%20starting%20dosage%20of%20TRULICITY%20is%200.75%20mg%20injected,%285.6%29%20and%20Adverse%20Reactions%20%286.1%29%5D.)

## Administration

<a id="trulicity-first-dose-in-office"></a>

### Should the first Trulicity dose be given in the office?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “Consider administering the patient’s first dose of Trulicity while they are in your office.”

Source: [TRULICITY: Getting Patients Started on Type 2 Diabetes Therapy, captured 2026-11-13](https://trulicity.lilly.com/hcp/getting-patients-started#:~:text=Consider%20administering%20the%20patient%E2%80%99s%20first,they%20are%20in%20your%20office.)

> “Give them a demonstration
> Consider giving them the first dose in the office
> Explain the Instructions for Use
> Show the demonstration pen
> Let them practice”

Source: [TRULICITY: Getting Patients Started on Type 2 Diabetes Therapy, captured 2026-11-13](https://trulicity.lilly.com/hcp/getting-patients-started#:~:text=Give%20them%20a%20demonstration,Let%20them%20practice)

## Related pages
- [Medical information: Trulicity (dulaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/specific-populations)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/guidelines)
